Sulagna Bhattacharya, Nanoscope Therapeutics CEO
Nanoscope’s eye disease gene therapy shows mixed results in PhII
Dallas-based biotech Nanoscope Therapeutics unveiled Phase II results on its gene therapy for a rare eye disease Thursday morning.
In the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
